Furthermore, HCV in circulation binding to plasma lipoprotein to form an infectious hybrid lipoviral particle (LVP) that promotes viral persistence and a high infection by limiting the access of nAbs to envelope glycoprotein are factors that pose a significant challenge to developing an effective HCV vaccine [60]. The gene discussed is ERVW-1; the disease is infection.